Lung Cancer Screening with Chest Computed Tomography in People Living with HIV: A Review by the Multidisciplinary CANCERVIH Working Group Alain Makinson,

Slides:

Advertisements

Similar presentations

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD

Advertisements

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

Brett W. Carter, MD, Edith M. Marom, MD, Frank C. Detterbeck, MD

Lung cancer screening: No more excuses

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients Camilla Maria T. Sagerup, MD, Milada.

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Primary Non-Hodgkin's Lymphoma of the Trachea

Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients Jean-Louis Pujol, MD, Patrick.

William S. Asch, Margaret J. Bia Advances in Chronic Kidney Disease

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Epidemic of Lung Cancer in Patients With HIV Infection

Frank Detterbeck, MD Journal of Thoracic Oncology

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Perception of Lung Cancer among the General Population and Comparison with Other Cancers Julien Mazières, MD, PhD, Jean-Louis Pujol, MD, PhD, Nikos Kalampalikis,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

The Role of Surgery in the Management of Primary Thymic Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Kimihiro Shimizu, MD, PhD, Izumi Takeyoshi,

Randomized Study on Early Detection of Lung Cancer with MSCT in Germany: Results of the First 3 Years of Follow-up After Randomization N. Becker, PhD,

Mitotic Inhibitors Journal of Thoracic Oncology

A Primer on Health Economic Evaluations in Thoracic Oncology

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer Mohammad Chakra, MD, Jean Louis Pujol,

The Number of Pulmonary Metastases: Influence on Practice and Outcome

S768I Mutation in EGFR in Patients with Lung Cancer

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early- Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized.

A Retrospective Analysis of Clinical Outcomes of Patients Older Than or Equal to 80 Years with Small Cell Lung Cancer Toshiyuki Noguchi, MD, Hideaki.

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of.

Large Bronchopleural Fistula After Surgical Resection: Secret to Success Isabelle Delanote, MD, Werner Budts, MD, PhD, Paul De Leyn, MD, PhD, Christophe.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small.

European Lung Cancer Conference (ELCC) 2016 Organisation

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

David Garfield, MD Journal of Thoracic Oncology

Epidemiology of Thymoma and Associated Malignancies

Gefitinib-Associated Propionibacterium acnes Pleural Empyema

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Lung Cancer Screening with Chest Computed Tomography in People Living with HIV: A Review by the Multidisciplinary CANCERVIH Working Group Alain Makinson, MD, PhD, Vincent Le Moing, MD, PhD, Jacques Reynes, MD, PhD, Tristan Ferry, MD, PhD, Armelle Lavole, MD, Isabelle Poizot-Martin, MD, Jean-Louis Pujol, MD, PhD, Jean-Philippe Spano, MD, PhD, Bernard Milleron, MD Journal of Thoracic Oncology Volume 11, Issue 10, Pages 1644-1652 (October 2016) DOI: 10.1016/j.jtho.2016.06.026 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 A representation of the number of lung cancers observed in the acquired immunodeficiency syndrome (AIDS) population (solid line), observed in the general population (dotted line), and expected in the general population (broken line). The expected numbers of cases in the general population are the numbers of lung cancers that would be observed in the general population if the composition of the general population had age and sex distributions identical to those in the AIDS population. Thus, according to this figure, advancing age for lung cancer screening with chest computed tomography is justified by the slightly advanced median age of lung cancer and the increased number of cases per age strata in the AIDS population in comparison with the expected numbers and median incidence if both populations were comparable (broken line). However, screening too early may miss most lung cancers in the AIDS population too. Adapted with permission from Shiels et al.41 Journal of Thoracic Oncology 2016 11, 1644-1652DOI: (10.1016/j.jtho.2016.06.026) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Excess cancer cases in persons living with human immunodeficiency virus (HIV) compared with in the general population from studies comparing HIV and cancer registries in the United States. A significant excess rate in persons living with HIV was revealed as from the 40- to 50-years age group. These results argue for a possible earlier lung cancer screening than that reserved for the general population at risk if the clinical numbers of excess lung cancers as from the 40- to 50-years age group are significant. HL, Hodgkin's lymphoma; KS, Kaposi's sarcoma; NHL, non-Hodgkin's lymphoma. Adapted with permission from Robbins et al.42 Journal of Thoracic Oncology 2016 11, 1644-1652DOI: (10.1016/j.jtho.2016.06.026) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions